Tassos Gianakakos
Chief Executive Officer at MYOKARDIA, INC.
Net worth: 117 331 $ as of 2024-03-30
Profile
Currently, Anastasios E. Gianakakos holds the position of Chief Executive Officer for MyoKardia, Inc. He is also on the board of LianBio. In the past Mr. Gianakakos was President & Senior VP-Business Development at Codexis, Inc., Process Engineer at Merck & Co., Inc., Director -Business Development at Maxygen, Inc. and Chief Business Officer & Senior Vice President at MAP Pharmaceuticals LLC. He received an undergraduate degree from Massachusetts Institute of Technology, a graduate degree from Northwestern University and an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
LIANBIO
0.35% | 2024-02-14 | 363,253 ( 0.35% ) | 117 331 $ | 2024-03-30 |
Tassos Gianakakos active positions
| Companies | Position | Start |
|---|---|---|
| MYOKARDIA, INC. | Chief Executive Officer | 2013-09-30 |
| LIANBIO | Director/Board Member | 2020-07-31 |
Prolaio, Inc.
 Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | President | - |
Former positions of Tassos Gianakakos
| Companies | Position | End |
|---|---|---|
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Corporate Officer/Principal | 2013-02-28 |
| MERCK & CO., INC. | Chief Tech/Sci/R&D Officer | 1996-12-31 |
| CODEXIS, INC. | President | - |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
Training of Tassos Gianakakos
| Massachusetts Institute of Technology | Undergraduate Degree |
| Northwestern University | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| CODEXIS, INC. | Process Industries |
| LIANBIO | Health Technology |
| Private companies | 4 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Prolaio, Inc.
Prolaio, Inc. BiotechnologyHealth Technology Prolaio, Inc. is a company founded in 2021 that engages in research and development of medical. The company is based in Scottsdale, AZ. | Health Technology |
- Stock Market
- Insiders
- Tassos Gianakakos
